Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth
Yong Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Ai‐Ming Yu(University at Buffalo, State University of New York), Ai-Xi Yu(Wuhan University), Yi-Feng Yu(Wuhan University), Jing-Xin Qiu(Roswell Park Comprehensive Cancer Center), Qiuxia Chen, Wei-Peng Wang(Cixian People's Hospital), Mei‐Juan Tu(University of California, Davis)
Cited by 64
Related Papers
Current trends in drug metabolism and pharmacokinetics
|Acta Pharmaceutica Sinica B|2019|391
RNA therapy: Are we using the right molecules?
|Pharmacology & Therapeutics|2018|172
Laboratory Diagnosis of Four Recent Sporadic Cases of Community-acquired SARS, Guangdong Province, China
|Emerging infectious diseases|2004|137
Negative pressure wound therapy improves bone regeneration by promoting osteogenic differentiation via the AMPK-ULK1-autophagy axis
|Autophagy|2021|105
Carnitine palmitoyltransferase 1C regulates cancer cell senescence through mitochondria-associated metabolic reprograming
|Cell Death and Differentiation|2018|94